Related Experiment Video

Updated: Jul 16, 2026

Estimating the Yield of Compounds on the TLC Plate via the Blue-LED Illumination Technique
06:14

Estimating the Yield of Compounds on the TLC Plate via the Blue-LED Illumination Technique

Published on: October 6, 2022

Tocotrienols potentiate lovastatin-mediated growth suppression in vitro and in vivo

Jennifer A McAnally1, Jagriti Gupta, Shradha Sodhani

  • 1Department of Biology, Texas Woman's University, P. O. Box 425888, Denton, TX 76204, USA.

Experimental Biology and Medicine (Maywood, N.J.)
|March 30, 2007
PubMed

Insights

Combining statins with vitamin E isomers like tocotrienols may offer a novel cancer therapy. This approach synergistically inhibits tumor growth by targeting HMG CoA reductase, potentially lowering effective statin doses.

Area of Science:

  • Biochemistry
  • Oncology
  • Pharmacology

Background:

  • 3-Hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase is crucial for the mevalonate pathway, essential for cell growth.
  • Statins, HMG CoA reductase inhibitors, show preclinical anti-cancer activity but are limited in clinical use by low efficacy at cardiovascular disease doses and dose-limiting toxicities at higher doses.
  • Tumor cells often have elevated HMG CoA reductase activity, which remains sensitive to isoprenoid-mediated down-regulation.

Purpose of the Study:

  • To investigate the synergistic effects of lovastatin and tocotrienols (vitamin E isomers) on tumor growth.
  • To explore the potential of combining isoprenoids with statins for cancer chemo-prevention and therapy.

Main Methods:

  • In vitro studies using murine B16 melanoma, human DU145 prostate carcinoma, and human A549 lung carcinoma cells to assess proliferation inhibition by lovastatin and tocotrienols alone and in combination.
  • In vivo studies using C57BL6 mice implanted with B16 melanoma cells, fed diets supplemented with lovastatin, d-delta-tocotrienol, or a combination of both.

Main Results:

  • Lovastatin, d-gamma-tocotrienol, and d-delta-tocotrienol demonstrated concentration-dependent inhibition of cancer cell proliferation.
  • A combination of lovastatin and d-gamma-tocotrienol exhibited synergistic inhibition of cell growth, significantly exceeding the additive effects of each agent alone in multiple cancer cell lines.
  • In vivo, only the combined administration of lovastatin and d-delta-tocotrienol significantly reduced tumor weight in mice.

Conclusions:

  • Co-administration of isoprenoids with statins can achieve synergistic inhibition of tumor HMG CoA reductase activity and tumor growth.
  • This combination therapy may allow for lower effective doses of statins, potentially mitigating toxicity and offering a novel strategy for cancer chemo-prevention and therapy.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Lipid Absorption01:24

Lipid Absorption

Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention01:05

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
Lipid Catabolism01:25

Lipid Catabolism

Triglycerides serve as crucial long-term energy storage molecules in microorganisms, providing a dense source of metabolic energy. Their breakdown is mediated by lipases, which hydrolyze triglycerides into glycerol and free fatty acids. Each of these components follows distinct metabolic pathways, ultimately contributing to ATP synthesis and cellular energy homeostasis.Glycerol MetabolismGlycerol, released from triglyceride hydrolysis, is phosphorylated by glycerol kinase to form...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...